Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 1, 2016, Pages 85-93

  Frisell, T ^a   Forsberg, L ^b   Nordin, N ^b   Kiesel, C ^b   Alfredsson, L ^b   Askling, J ^a,b   Hillert, J ^b   Olsson, T ^b   Piehl, F ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

drug survival; fingolimod; health services research; Multiple sclerosis; natalizumab; treatment outcome

Indexed keywords

FINGOLIMOD; NATALIZUMAB; IMMUNOLOGIC FACTOR;

ADULT; ADVERSE DRUG REACTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE; MULTIPLE SCLEROSIS SEVERITY SCORE; NEUROLOGIC DISEASE ASSESSMENT; REGISTER; SWEDISH CITIZEN; SYMBOL DIGIT MODALITIES TEST; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; SWEDEN; TIME FACTOR; TREATMENT OUTCOME; ACUTE LEUKEMIA; AGE; ALLERGIC REACTION; ASSESSMENT OF HUMANS; FATIGUE; HEART BLOCK; HERPES SIMPLEX; HYPERTRANSAMINASEMIA; INFECTION; JC VIRUS; LYMPHOCYTOPENIA; MACULAR EDEMA; MS IMPACT SCALE; MS SEVERITY SCORE; SENSITIVITY ANALYSIS; TREATMENT WITHDRAWAL;

ADULT; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NATALIZUMAB; REGISTRIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84951033355     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515579216     Document Type: Article

References (20)

1. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-556.
2. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.
3. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
4. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
5. Holmen C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler 2011; 17: 708-719.
6. Ahlgren C, Oden A, Lycke J,. High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler 2011; 17: 901-908.
7. Hedstrom AK, Baarnhielm M, Olsson T, et al. Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009; 73: 696-701.
8. Hedstrom AK, Hillert J, Olsson T, et al. Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. JAMA Neurol 2014; 71: 300-305.
9. Kurtzke JF,. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-1452.
10. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144-1151.
11. Parmenter BA, Weinstock-Guttman B, Garg N, et al. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler 2007; 13: 52-57.
12. Hobart J, Lamping D, Fitzpatrick R, et al. The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. A Journal of Neurology 2001; 124 (5): 962-973.
13. Gray RJ,. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
14. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med 2010; 362: 402-415.
15. Hedstrom A, Alfredsson L, Lundkvist Ryner M, et al. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler 2013; 20: 1081-1085.
16. Matell H, Lycke J, Svenningsson A, et al. Age-dependent effects on the treatment response of natalizumab in MS patients. Mult Scler 2015; 21: 48-56.
17. Tur C, Tintore M, Vidal-Jordana A, et al. Risk acceptance in multiple sclerosis patients on natalizumab treatment. PloS One 2013; 8: e82796.
18. Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77: 425-435.
19. Piehl F,. A changing treatment landscape for multiple sclerosis: Challenges and opportunities. J Intern Med 2014; 275: 364-381.
20. Jokubaitis VG, Li V, Kalincik T, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology 2014; 82: 1204-1211.